Mountain Lakes, NJ, United States of America

Vincent Stewart Madison

This inventor holds 46 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Schering Corporation, Hoffmann-La Roche Inc., Merck Sharp + Dohme Corp.. Active years: 1989-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Vincent Stewart Madison. Retrieved from https://idiyas.com/inventor/vincent-stewart-madison

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 46 (Patent Applications = 3)

% Patents Active = 50.0

CIPO Patents = 2

EPO Patents = 9 (Patent Applications = 2)

Average Co-Inventor Count = 7.5

ph-index = 12

Forward Citations = 376(Granted Patents)

Location History:

Moutain Lakes, NJ (US) (2010)
Mountain Lakes, NJ (US) (1989 - 2014)
Ukiah, CA (US) (2009 - 2014)

Company Filing History:

Hoffmann-La Roche Inc.

patents

4 out of 2,405

Merck Sharp + Dohme Corp.

patents

4. 3 out of 52

Pharmacopeia Drug Discovery, Inc.

where one patent can have more than one assignee

Years Active: 1989-2014

Loading Chart...

Areas of Expertise:

ERK Inhibitors

Cyclin Dependent Kinase

Aurora Kinase

Hepatitis C

Pyrazolopyrimidines

HDM2 Polypeptides

Inflammatory Disorders

N-heteroaryl Compounds

Polynucleotides

Crystalline Forms

Protein Kinase B

Macrocyclic Inhibitors

46 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8710188 - Factor IXa crystals, related complexes and methods (2014-04-29),

2. 8673924 - Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors (2014-03-18),

3. 8546404 - Compounds that are ERK inhibitors (2013-10-01),

4. 8440443 - MEK1 polypeptides (2013-05-14),

5. 8088611 - Kinase domain polypeptide of human protein kinase B gamma (AKT3) (2012-01-03),

6. 8048663 - Crystal of pregnane X receptor fused to steroid receptor coactivator-1 (2011-11-01),

7. 8034907 - Polynucleotides encoding soluble, stable forms of human double minute 2 polypeptides (2011-10-11),

8. 7968683 - Factor IXa crystals, related complexes and methods (2011-06-28),

9. 7888474 - HDM2 polypeptides (2011-02-15),

10. 7879890 - Compounds for the treatment of inflammatory disorders (2011-02-01),

11. 7824491 - Method for crystallizing aurora 2 kinase catalytic domain polypeptide (2010-11-02),

12. 7807683 - N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors (2010-10-05),

13. 7807672 - Compounds that are ERK inhibitors (2010-10-05),

14. 7785879 - Pregnane X receptor compositions, crystals and uses thereof (2010-08-31),

15. 7776589 - Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3) (2010-08-17),

Title: Innovator Profile: Vincent Stewart Madison

Introduction:

Vincent Stewart Madison is an accomplished inventor based in Mountain Lakes, NJ, renowned for his extensive contributions to the field of medicinal chemistry. With a remarkable portfolio of 46 patents, Madison has been at the forefront of developing innovative solutions in drug discovery and design.

Latest Patents:

Among his latest patents, one highlights the invention of Factor IXa crystals and related complexes, which also includes methods for identifying inhibitors of factor IXa. This invention could pave the way for advancements in treating various coagulation disorders. Another significant patent involves substituted pyrazolo[1,5-a]pyrimidines as cyclin-dependent kinase inhibitors. This invention outlines methods for inhibiting specific cyclin-dependent kinases in patients, providing therapeutic opportunities for treating diseases associated with these kinases.

Career Highlights:

Vincent Stewart Madison has collaborated with prominent companies during his career, including Schering Corporation and Hoffmann-La Roche Inc. His work has focused on harnessing the power of chemical compounds to create novel pharmacological agents.

Collaborations:

Throughout his journey, Madison has worked alongside talented colleagues, including Paul Reichert and Thierry Olivier Fischmann. These collaborations have fostered an environment of creativity and innovation, allowing for the exploration of new therapeutic pathways.

Conclusion:

Vincent Stewart Madison stands out as an influential inventor in the pharmaceutical landscape. His substantial number of patents and inventive spirit continue to impact the field of medicinal chemistry, showcasing the importance of innovation in addressing medical challenges.

Profile summary based on public USPTO records.